Hypertensive cerebral hemorrhage with neurologic dysfunction
Conditions
Interventions
Experimental group:NGF+Citicoline
The control group:Citicoline
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years male and female; 2. Diagnosed as Supratentorial intracerebral hemorrhage in basal ganglia by Skull CT examination, hematoma volume 10 ~ 40ml; 3. With a hypertension history and exclusion of other source of spontaneous intracerebral hemorrhage, systolic blood pressure = 140 mmHg in seizure; 4. Patients were ill about 3 days, with stable vital signs, GCS=9 5. Conservative treatment.
Exclusion criteria
Exclusion criteria: 1. Non-hypertensive intracerebral hemorrhage, such as atherosclerosis, amyloidosis, arteriovenous malformations; 2. Aneurysm or bleeding stroke caused by tumors, such as intracranial aneurysms; 3. Acute brain injury; 4. Previous history of craniotomy; 5. Multiple intracranial hemorrhage (including two or more anatomical sites and bleeding), contained a single intraventricular hemorrhage, cerebral hemorrhage, brain stem hemorrhage; 6. Previous history of cerebral infarction; 7. The patients' medical history was unknown before admission; 8. Patients with previous mental disorder or neurological dysfunction; 9. The patients mounted bracket or had took anticoagulant drugs over a year and the doses were greater than ordinary (such as aspirin =100mg/d); 10. Hepatic dysfunction (transaminases more than 2 times the upper limit of normal), renal dysfunction (creatinine exceeds 1.5 times the upper limit of normal), cardiac dysfunction, severe lung infections (such as sepsis disorders such serious complications) or suffered from other serious systemic diseases (such as systemic vascular disease, coagulation disorders, collagen diseases, diabetes, epilepsy, etc.); 11. With intracranial hypertension symptoms and history 12. Patients with severe peripheral nerve injury affected the clinical trials evaluation; 13. Patients were malignancy or ongoing anti-tumor therapy; 14. The use of other similar neurotrophic drugs during the observation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS;GCS;GOS-E;mRS;ADL;EEG;SEP; | — |
Countries
China
Contacts
Public ContactJianning Zhang?Rongcai Jiang
Tianjin Medical University General Hospital
Outcome results
None listed